Sign Out
Dapagliflozin and metformin HCl (as extended-release) tablets are contraindicated in patients with: End-stage renal disease, dialysis patients, or severe renal impairment (eGFR <30 mL/min/1.73 m2).
History of a severe allergic reaction to any of the excipients in dapagliflozin and metformin HCl (as extended-release) tablets, dapagliflozin, or metformin HCl. Dapagliflozin has been linked to serious hypersensitivity responses, such as angioedema and anaphylaxis.
Diabetic ketoacidosis and other forms of acute or chronic metabolic acidosis, with or without coma. Insulin should be used to treat diabetic ketoacidosis.
Continue with Google